Checkpoint inhibitors for gastroesophageal cancers: dissecting heterogeneity to better understand their role in first-line and adjuvant therapy

Checkpoint inhibitors for gastroesophageal cancers: dissecting heterogeneity to better understand their role in first-line and adjuvant therapy

Gastroesophageal adenocarcinoma (GEA) and squamous esophageal cancer (ESCC) are responsible for >1 million deaths annually globally. Until now, patients with metastatic GEA and ESCC could anticipate survival of

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annals of oncology 2021-05, Vol.32 (5), p.590-599
Hauptverfasser: Smyth, E.C., Gambardella, V., Cervantes, A., Fleitas, T.
Format: Artikel
Sprache:eng
Schlagworte:
Antibodies, Monoclonal, Humanized
chemoimmunotherapy
Combined Modality Therapy
esophageal cancers
Esophageal Neoplasms - drug therapy
gastric cancer
Humans
immunotherapy
Nivolumab - therapeutic use
Stomach Neoplasms - drug therapy
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Gastroesophageal adenocarcinoma (GEA) and squamous esophageal cancer (ESCC) are responsible for >1 million deaths annually globally. Until now, patients with metastatic GEA and ESCC could anticipate survival of
ISSN:0923-7534
1569-8041
DOI:10.1016/j.annonc.2021.02.004